Literature DB >> 18632869

Identification of an arginine-rich motif in human papillomavirus type 1 E1;E4 protein necessary for E4-mediated inhibition of cellular DNA synthesis in vitro and in cells.

Sally Roberts1, Sarah R Kingsbury, Kai Stoeber, Gillian L Knight, Phillip H Gallimore, Gareth H Williams.   

Abstract

Productive infections by human papillomaviruses (HPVs) are restricted to nondividing, differentiated keratinocytes. HPV early proteins E6 and E7 deregulate cell cycle progression and activate the host cell DNA replication machinery in these cells, changes essential for virus synthesis. Productive virus replication is accompanied by abundant expression of the HPV E4 protein. Expression of HPV1 E4 in cells is known to activate cell cycle checkpoints, inhibiting G(2)-to-M transition of the cell cycle and also suppressing entry of cells into S phase. We report here that the HPV1 E4 protein, in the presence of a soluble form of the replication-licensing factor (RLF) Cdc6, inhibits initiation of cellular DNA replication in a mammalian cell-free DNA replication system. Chromatin-binding studies show that E4 blocks replication initiation in vitro by preventing loading of the RLFs Mcm2 and Mcm7 onto chromatin. HPV1 E4-mediated replication inhibition in vitro and suppression of entry of HPV1 E4-expressing cells into S phase are both abrogated upon alanine replacement of arginine 45 in the full-length E4 protein (E1;E4), implying that these two HPV1 E4 functions are linked. We hypothesize that HPV1 E4 inhibits competing host cell DNA synthesis in replication-activated suprabasal keratinocytes by suppressing licensing of cellular replication origins, thus modifying the phenotype of the infected cell in favor of viral genome amplification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632869      PMCID: PMC2546886          DOI: 10.1128/JVI.01080-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network.

Authors:  J Doorbar; S Ely; J Sterling; C McLean; L Crawford
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

2.  Phosphorylation of the human papillomavirus type 1 E4 proteins in vivo and in vitro.

Authors:  R J Grand; J Doorbar; K J Smith; I Coneron; P H Gallimore
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

3.  Nuclear DNA synthesis in vitro is mediated via stable replication forks assembled in a temporally specific fashion in vivo.

Authors:  N H Heintz; B W Stillman
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

4.  Association of the human papillomavirus type 11 E1()E4 protein with cornified cell envelopes derived from infected genital epithelium.

Authors:  J T Bryan; D R Brown
Journal:  Virology       Date:  2000-11-25       Impact factor: 3.616

5.  A human papilloma virus type 11 transcript encoding an E1--E4 protein.

Authors:  M Nasseri; R Hirochika; T R Broker; L T Chow
Journal:  Virology       Date:  1987-08       Impact factor: 3.616

6.  Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin.

Authors:  S Tada; A Li; D Maiorano; M Méchali; J J Blow
Journal:  Nat Cell Biol       Date:  2001-02       Impact factor: 28.824

7.  DNA replication licensing and human cell proliferation.

Authors:  K Stoeber; T D Tlsty; L Happerfield; G A Thomas; S Romanov; L Bobrow; E D Williams; G H Williams
Journal:  J Cell Sci       Date:  2001-06       Impact factor: 5.285

8.  Analysis of HPV-1 E4 gene expression using epitope-defined antibodies.

Authors:  J Doorbar; H S Evans; I Coneron; L V Crawford; P H Gallimore
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

9.  E1 empty set E4 protein of human papillomavirus type 16 associates with mitochondria.

Authors:  Kenneth Raj; Samuel Berguerand; Shirley Southern; John Doorbar; Peter Beard
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  DNA replication licensing and cell cycle kinetics of oligodendroglial tumours.

Authors:  S B Wharton; S Hibberd; K L Eward; D Crimmins; D A Jellinek; D Levy; K Stoeber; G H Williams
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  6 in total

1.  A cyclin-binding motif in human papillomavirus type 18 (HPV18) E1^E4 is necessary for association with CDK-cyclin complexes and G2/M cell cycle arrest of keratinocytes, but is not required for differentiation-dependent viral genome amplification or L1 capsid protein expression.

Authors:  Gillian L Knight; Alice G Pugh; Emma Yates; Ian Bell; Regina Wilson; Cary A Moody; Laimonis A Laimins; Sally Roberts
Journal:  Virology       Date:  2011-01-31       Impact factor: 3.616

Review 2.  DNA replication licensing control and rereplication prevention.

Authors:  Chonghua Li; Jianping Jin
Journal:  Protein Cell       Date:  2010-02-23       Impact factor: 14.870

Review 3.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

4.  Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis.

Authors:  Zhikang Qian; Van Leung-Pineda; Baoqin Xuan; Helen Piwnica-Worms; Dong Yu
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

5.  SMC1-mediated intra-S-phase arrest facilitates bocavirus DNA replication.

Authors:  Yong Luo; Xuefeng Deng; Fang Cheng; Yi Li; Jianming Qiu
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

6.  Human papillomavirus type 1 E1^E4 protein is a potent inhibitor of the serine-arginine (SR) protein kinase SRPK1 and inhibits phosphorylation of host SR proteins and of the viral transcription and replication regulator E2.

Authors:  Emma L Prescott; Claire L Brimacombe; Margaret Hartley; Ian Bell; Sheila Graham; Sally Roberts
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.